The preclinical natural history of serous ovarian cancer: Defining the target for early detection

PLoS Medicine

Volumn 6, Issue 7, 2009, Pages

  Brown, Patrick O ^a,b   Palmer, Chana ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c Canary Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CLINICAL EXAMINATION; CONTROLLED STUDY; EARLY DIAGNOSIS; EXPERIMENTAL MODEL; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; OCCULT CANCER; ONCOGENE; OVARY; OVARY CANCER; SALPINGOOOPHORECTOMY; SCREENING TEST; TUMOR VOLUME; UTERINE TUBE;

EARLY DIAGNOSIS; FEMALE; GENES, BRCA1; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREVALENCE; SEROUS MEMBRANE;

EID: 68049122014     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000114     Document Type: Article

References (63)

1. ACS (2008) Cancer facts and figures 2008. Atlanta: American Cancer Society.
2. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, et al. (2007) Global cancer facts and figures 2007. Atlanta: American Cancer Society.
3. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, et al. (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232. doi:10.1371/journal.pmed.0050232.
4. Soslow RA (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27: 161-174.
5. Kosary C (2007) Cancer of the ovary. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, et al. (2007) SEER survival monograph: cancer survival among adults: US SEER Program, 1988-2001, patient and tumor characteristics. Bethesda (Maryland): National Cancer Institute, SEER Program.
6. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, et al. (2003) The case for early detection. Nat Rev Cancer 3: 243-252.
7. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, et al. (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7: 223-229.
8. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, et al. (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296: 185-192.
9. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609-1615.
10. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616-1622.
11. Agoff SN, Garcia RL, Goff B, Swisher E (2004) Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. Am J Surg Pathol 28: 1112-1114.
12. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, et al. (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25: 3985-3990.
13. Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, et al. (2006) Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol 30: 1222-1230.
14. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25: 1283-1289.
15. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, et al. (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100: 58-64.
16. Laki F, Kirova YM, This P, Plancher C, Asselain B, et al. (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109: 1784-1790.
17. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM (2006) Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 194: 1702-1709.
18. Leeper K, Garcia R, Swisher E, Goff B, Greer B, et al. (2002) Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87: 52-56.
19. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, et al. (2000) Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18: 2728-2732.
20. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, et al. (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30: 230-236.
21. Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, et al. (2004) Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90: 1492-1497.
22. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, et al. (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23: 127-132.
23. Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, et al. (2005) Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 97: 476-482.
24. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, et al. (2001) Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80: 176-180.
25. Deligdisch L, Gil J, Kerner H, Wu HS, Beck D, et al. (1999) Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer 86: 1544-1550.
26. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, et al. (1996) Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88: 1810-1820.
27. Freeman J, Hutchison GB (1980) Prevalence, incidence and duration. Am J Epidemiol 112: 707-723.
28. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, et al. (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104: 2807-2816.
29. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, et al. (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98: 1694-1706.
30. R-Development-Core-Team (2007) R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
31. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, et al. (2006) Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 13: 1-7.
32. Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, et al. (2002) Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20: 1570-1577.
33. Bell DA, Scully RE (1994) Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 73: 1859-1864.
34. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, et al. (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31: 161-169.
35. van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, et al. (2007) Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109: 1887-1896.
36. Ries L, Harkins D, Krapcho M, Mariotto A, Miller B, et al. (2007) SEER cancer statistics review, 1975-2004. Bethesda (Maryland): National Cancer Institute.
37. Zahl PH, Maehlen J, Welch HG (2008) The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 168: 2311-2316.
38. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, et al. (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283: 2260-2265.
39. Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, Garlinghouse-Jones K, et al. (2004) Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 23: 29-34.
40. Dorum A, Heimdal K, Lovslett K, Kristensen G, Hansen LJ, et al. (1999) Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 78: 906-911.
41. Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, et al. (2006) Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 16 Suppl 1: 54-59.
42. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, et al. (2007) No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 96: 1335-1342.
43. Hogg R, Friedlander M (2004) Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22: 1315-1327.
44. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, et al. (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353: 1207-1210.
45. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, et al. (2007) A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer.
46. Lacey JV Jr, Greene MH, Buys SS, Reding D, Riley TL, et al. (2006) Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol 108: 1176-1184.
47. Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, et al. (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 23: 5588-5596.
48. Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, et al. (2003) Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 21: 378-385.
49. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, et al. (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 114: 1500-1509.
50. Horiuchi A, Itoh K, Shimizu M, Nakai I, Yamazaki T, et al. (2003) Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol 88: 309-317.
51. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, et al. (2004) Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10: 2473-2481.
52. Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, et al. (2002) Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 21: 407-411.
53. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, et al. (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195.
54. Lutz AM, Willmann JK, Cochran FV, Ray P, Gambhir SS (2008) Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med 5: e170. doi:10.1371/journal.pmed.0050170.
55. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102: 7677-7682.
56. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, et al. (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072.
57. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP (2007) Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res 13: 4422-4428.
58. Yale University (2008) New test detects early stage ovarian cancer with 99 percent accuracy. Science Daily. 13 February 2008. Available at: www.sciencedaily.com/releases/2008/02/080212144500.htm.
59. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, et al. (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10: 327-340.
60. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, et al. (2009) Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113: 775-782.
61. Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, et al. (2008) US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246: 508-518.
62. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17: 545-580.
63. Merrill RM (2008) Hysterectomy Surveillance in the United States, 1997 through 2005. Med Sci Monit 14: CR24-31.